Krasner CN, et al. - Since outcomes for women with optimally cytoreduced epithelial ovarian cancer may be improved with intraperitoneal (IP) chemotherapy, researchers conducted two phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without (Trial A) and with bevacizumab (Trial B) to assess safety and tolerability, pathologic CR rate (Trial A), and the rate of completion of IP cycles of therapy (Trial B). In both trials, 81 patients were treated. Compared with IV, the peak plasma concentration of free platinum was about 40% lower when carboplatin was given IP. With and without concomitant bevacizumab, weekly administered IP carboplatin and IP paclitaxel is tolerable and safe with similar activity in these 2 trials.